Any claim that it is not easy to spot OMICS conferences as “problematic” is preposterous. Five minutes of Googling would do it. Any suggestion that these companies need to await the outcome of an FTC complaint to determine that OMICS (or other publications) are not appropriate venues for publishing their research is silly. The websites of (and the spam from) many of these journals give lip service to peer review and quality editing, but they are filled with obvious warning signs that belie these protestations.
Of course, big pharma is hardly the only source of revenue for OMICS, BIT Group Global, and the flotilla of other flaky publishers and conference organizers. Universities need policies that discourage their faculty from padding CVs with membership on the editorial boards of certain journals; from resorting to publishing in these journals; and from dallying in Dalian.